Nemus licenses synthetic cannabinoid production tech from Teewinot
Nemus Biosciences has licensed rights to an in-vitro synthetic cannabinoid manufacturing method developed by Teewinot Life Sciences.
Archives for June 13, 2016
US FDA to review Amgen's Humira biosimilar in July
The US FDA has set a date to review Amgen’s ABP501, a biosimilar version of AbbVie’s rheumatoid arthritis biologic Humira (adalimumab).
Biopharma CRO round-up: Eurofins, Charles River and more
An expansion in Ireland for Eurofins, new cell screening tech for Cyprotex, and an mRNA development deal for Charles River. Welcome to Biopharma-Reporter’s bio-service round-up.
BIO 2016
Technology, not capacity, driving Catalent’s biologics strategy
Differentiated technologies buoyed by the recent $600m conjugation deal with Roche is driving Catalent’s biologics business, the firm told Biopharma-Reporter at BIO.